May 24, 2022 -- Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers, according to co-founder Dr. Bernhard Gentner, PhD.
ScienceBoard.net spoke to Gentner at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC, about Temferon, which is under investigation in a phase I/IIa clinical trial in newly diagnosed glioblastoma multiforme patients.
"We have treated so far 16 patients with this strategy," Gentner said, noting that early results are promising with T cell response activation in some patients. "We did this in glioblastoma patients, which is really a terrible tumor which has no cure today."
Watch the video below to learn more.
Copyright © 2022 scienceboard.net